ProCE Banner Activity

Pooled Analysis of Filgotinib Trials in RA: Incidence and Risk Factors for VTE and MACE

Slideset Download
Conference Coverage
Pooled analysis of 7 phase II/III trials suggests that the investigational JAK inhibitor is associated with low rates of VTE and MACE, with no major safety signals among those with cardiovascular risk factors.

Released: November 13, 2020

Expiration: November 12, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

Gilead Sciences, Inc.

Sanofi Genzyme Corp